e.castellanos
Submits third-party assay reports on material purchased directly. Based in Ghent.
Section 1
Contribution
Purchases material, pays for assays, and submits the resulting reports to the index.
Records submitted
9
n=9
Annotations
0
n=0
Median purity submitted
99.23%
n=9
Suppliers covered
9
n=9
Section 2
Records submitted
A submitter chose to buy this material and to pay for this assay. That choice is the selection mechanism behind the whole index and it is not random.
| Report | Compound | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042256 | Tirzepatide | TFC | TFC-2605-G9870 | Janoshik | 2026-Q3 | 98.97 | 6.26 | 89.2 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042051 | Retatrutide | HYB | HYB-2604-D6658 | Nordanalyt | 2026-Q2 | 98.68 | 3.94 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041730 | TB-500 | TFS | TFS-{CAT}-9979 | Janoshik | 2026-Q1 | 99.93 | 4.12 | — | Buyer-sourced | 0 | PASS |
| AX-2025-021090 | Cagrilintide | BCH | BCH-2509-A4594 | Janoshik | 2025-Q4 | 99.20 | 6.54 | 96.7 | Buyer-sourced | 0 | PASS |
| AX-2025-019879 | MK-677 (Ibutamoren mesylate) | HJ | HJ-2501-G5680 | Medutest | 2025-Q2 | 99.93 | 5.65 | — | Buyer-sourced | 1 | FAIL |
| AX-2025-018770 | MK-677 (Ibutamoren mesylate) | FGP | FGP-2502-F7880 | Medutest | 2025-Q2 | 99.32 | 3.90 | — | Buyer-sourced | 0 | FAIL |
| AX-2025-018959 | Tirzepatide | ASY | ASY-{CAT}-1489 | Janoshik | 2025-Q1 | 98.62 | 6.35 | 98.1 | Buyer-sourced | 0 | PASS |
| AX-2025-018410 | Semaglutide | WWB | WWB-2502-W1846 | PeptideMeter | 2025-Q1 | 99.23 | 5.88 | 92.7 | Buyer-sourced | 1 | MARGINAL |
| AX-2024-004553 | Semaglutide | JEEP | JEEP-2401-R8036 | Kestrel | 2024-Q2 | 99.71 | 7.49 | 99.7 | Buyer-sourced | 0 | PASS |